Takeda Pharmaceutical Co Ltd ADR
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $15.72
- Today's High:
- $15.87
- Open Price:
- $15.8
- 52W Low:
- $12.28
- 52W High:
- $17.15
- Prev. Close:
- $15.49
- Volume:
- 2297128
Company Statistics
- Market Cap.:
- $48.20 billion
- Book Value:
- 2226.0315
- Revenue TTM:
- $4,113.63 billion
- Operating Margin TTM:
- 15.35%
- Gross Profit TTM:
- $2,441.70 billion
- Profit Margin:
- 7.33%
- Return on Assets TTM:
- 2.74%
- Return on Equity TTM:
- 4.55%
Company Profile
Takeda Pharmaceutical Co Ltd ADR had its IPO on 2008-10-27 under the ticker symbol TAK.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Takeda Pharmaceutical Co Ltd ADR has a staff strength of 49,095 employees.
Stock update
Shares of Takeda Pharmaceutical Co Ltd ADR opened at $15.8 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $15.72 - $15.87, and closed at $15.81.
This is a +2.07% increase from the previous day's closing price.
A total volume of 2,297,128 shares were traded at the close of the day’s session.
In the last one week, shares of Takeda Pharmaceutical Co Ltd ADR have increased by +2.73%.
Takeda Pharmaceutical Co Ltd ADR's Key Ratios
Takeda Pharmaceutical Co Ltd ADR has a market cap of $48.20 billion, indicating a price to book ratio of 0.9814 and a price to sales ratio of 0.0126.
In the last 12-months Takeda Pharmaceutical Co Ltd ADR’s revenue was $4,113.63 billion with a gross profit of $2,441.70 billion and an EBITDA of $1,235.51 billion. The EBITDA ratio measures Takeda Pharmaceutical Co Ltd ADR's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Takeda Pharmaceutical Co Ltd ADR’s operating margin was 15.35% while its return on assets stood at 2.74% with a return of equity of 4.55%.
In Q2, Takeda Pharmaceutical Co Ltd ADR’s quarterly earnings growth was a negative -15.5% while revenue growth was a positive 8.9%.
Takeda Pharmaceutical Co Ltd ADR’s PE and PEG Ratio
- Forward PE
- 9.7276
- Trailing PE
- 23.3182
- PEG
- 0.5932
Its diluted EPS in the last 12-months stands at $0.66 per share while it has a forward price to earnings multiple of 9.7276 and a PEG multiple of 0.5932. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Takeda Pharmaceutical Co Ltd ADR’s profitability.
Takeda Pharmaceutical Co Ltd ADR stock is trading at a EV to sales ratio of 0.0201 and a EV to EBITDA ratio of 0.0762. Its price to sales ratio in the trailing 12-months stood at 0.0126.
Takeda Pharmaceutical Co Ltd ADR stock pays annual dividends of $180 per share, indicating a yield of 4.29% and a payout ratio of 86.56%.
Balance sheet and cash flow metrics
- Total Assets
- $14,792.74 billion
- Total Liabilities
- $2,501.74 billion
- Operating Cash Flow
- $-266530000000.00
- Capital Expenditure
- $269.24 billion
- Dividend Payout Ratio
- 86.56%
Takeda Pharmaceutical Co Ltd ADR ended 2024 with $14,792.74 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $14,792.74 billion while shareholder equity stood at $6,921.05 billion.
Takeda Pharmaceutical Co Ltd ADR ended 2024 with $0 in deferred long-term liabilities, $2,501.74 billion in other current liabilities, 1676411000000.00 in common stock, $1,490.10 billion in retained earnings and $5,182.13 billion in goodwill. Its cash balance stood at $316.38 billion and cash and short-term investments were $368.61 billion. The company’s total short-term debt was $416,860,000,000 while long-term debt stood at $4,330.25 billion.
Takeda Pharmaceutical Co Ltd ADR’s total current assets stands at $2,472.02 billion while long-term investments were $393.53 billion and short-term investments were $52.23 billion. Its net receivables were $825.48 billion compared to accounts payable of $440.92 billion and inventory worth $1,083.37 billion.
In 2024, Takeda Pharmaceutical Co Ltd ADR's operating cash flow was $-266530000000.00 while its capital expenditure stood at $269.24 billion.
Comparatively, Takeda Pharmaceutical Co Ltd ADR paid $0.87 in dividends in 2024.
Other key metrics
- Current Trading Price
- $15.81
- 52-Week High
- $17.15
- 52-Week Low
- $12.28
- Analyst Target Price
- $19.12
Takeda Pharmaceutical Co Ltd ADR stock is currently trading at $15.81 per share. It touched a 52-week high of $17.15 and a 52-week low of $17.15. Analysts tracking the stock have a 12-month average target price of $19.12.
Its 50-day moving average was $15.34 and 200-day moving average was $15.81 The short ratio stood at 2.29 indicating a short percent outstanding of 0%.
Around 0.5% of the company’s stock are held by insiders while 267% are held by institutions.
Frequently Asked Questions About Takeda Pharmaceutical Co Ltd ADR
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, JCR Pharmaceuticals, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.